Senhwa concludes enrolment in Phase II oral Covid-19 drug trial clinicaltrialsarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicaltrialsarena.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focused on human efficacy and innovation of first-in-class therapeutics.
/PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and.
Share:
TAIPEI and SAN DIEGO, Dec. 23. 2020 /PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a Study May Proceed letter from the US Food and Drug Administration (FDA) to begin a Phase Ib study evaluating CX-5461, a first-in-class G-quadruplex stabilizer, to treat solid tumors with
BRCA2 or PALB2 mutations. The FDA s approval of our Phase Ib clinical trial application for testing CX-5461 in patients with
BRCA2 or PALB2 mutations is an important milestone and marks a new paradigm in the treatment of cancers with specific pathogenic mutations, stated Dr. John Soong, the Chief Medical Officer of Senhwa Biosciences.